Sai Parenteral's IPO gets mixed reviews; does it merit your investment?

Analysts at SBI Securities, and Ashika Institutional Equities have recommended subscribing to the issue for the long term, while those at Swastika Investmart have assigned an 'Avoid' rating

Go to News Site